Almirall

Almirall, a Pharmaceutical Preparation Manufacturing company headquartered in Spain, reported total carbon emissions of approximately 147,641,000 kg CO2e in 2024. This figure includes Scope 1 emissions of around 5,742,000 kg CO2e, Scope 2 emissions (location-based) of approximately 3,752,000 kg CO2e, and Scope 3 emissions totalling about 141,899,000 kg CO2e. In 2023, the company's total emissions were approximately 162,824,000 kg CO2e, comprising Scope 1 emissions of roughly 6,154,000 kg CO2e, Scope 2 emissions (location-based) of about 4,868,000 kg CO2e, and Scope 3 emissions of around 156,670,000 kg CO2e. Looking back to 2022, Almirall's total emissions were approximately 152,930,000 kg CO2e, with Scope 1 at about 7,449,000 kg CO2e, Scope 2 (location-based) at around 4,543,000 kg CO2e, and Scope 3 at roughly 145,483,000 kg CO2e.

Almirall is committed to ambitious climate action. The company has set near-term Science Based Targets initiative (SBTi) approved goals to reduce absolute Scope 1 and 2 GHG emissions by 50% by 2030, from a 2019 base year. Additionally, Almirall aims to reduce absolute Scope 3 GHG emissions by 28% by 2030, also from a 2019 base year. For the long term, Almirall has set an overall net-zero target, committing to reach net-zero greenhouse gas emissions across the entire value chain by 2050, from the same 2019 base year. This includes a commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 90% by 2050. The company also states a commitment to continue actively sourcing 100% renewable electricity through 2030.